UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
‘Korea should lead precision medicine -- now’
by Nam Doo-hyun
2017-11-06 06:00
Celltrion’s US sales of Remsima up 48% in Q3
by Nam Doo-hyun
2017-11-01 15:51
‘Government’s undue intervention hinders growth of CROs’
by Nam Doo-hyun
2017-10-27 17:35
‘Early diagnosis more important than immunotherapy to cure lung cancer’
by Nam Doo-hyun
2017-10-25 15:22
Will induced pluripotent stem cells avoid ethical issues?
by Nam Doo-hyun
2017-10-17 15:25
라인
Stem cell treatment for diabetes nears
by Nam Doo-hyun
2017-10-13 15:47
Celltrion rises high in Korean stock market
by Nam Doo-hyun
2017-10-11 16:11
KDA unveils new guidelines on antidiabetic therapy
by Nam Doo-hyun
2017-09-29 15:35
‘Short disposable syringe increases insulin treatment effect’
by Nam Doo-hyun
2017-09-29 10:30
Korean drugmakers’ smart factories at ‘base level’
by Nam Doo-hyun
2017-09-28 16:00
라인
Drugmakers need to differentiate big data from ‘large data’
by Nam Doo-hyun
2017-09-27 17:44
Can Celltrion, Samsung make stable earnings with biosimilar?
by Nam Doo-hyun
2017-09-26 17:31
‘Keytruda will beat Opdivo in US because of biomarker’
by Nam Doo-hyun
2017-09-26 15:57
With rival out, expectations growing on Genexine
by Nam Doo-hyun
2017-09-25 13:52
State agency points to gender gap in medical research
by Nam Doo-hyun
2017-09-21 17:13
라인
Korea lags far behind in biomedical R&D: report
by Nam Doo-hyun
2017-09-21 16:14
Combination vaccines expand range of prevention
by Nam Doo-hyun
2017-09-21 15:23
Sillajen emerges as biggest beneficiary of preferential listing
by Nam Doo-hyun
2017-09-20 17:22
Technology transfer to Genexine imminent
by Nam Doo-hyun
2017-09-19 18:02
Pharmaceutical industry leading new growth in Korea: report
by Nam Doo-hyun
2017-09-18 14:50
-
이전
11
12
13
14
15
16
17
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top